Overview
What Surgimate does: Surgimate provides surgical scheduling software for medical practices, hospitals, and surgical centers to streamline the booking of surgeries, maximize operating room block time, and boost surgical revenue. How the product works: The platform automates and coordinates surgery scheduling to improve throughput and reduce scheduling costs, with a subscription-based model that charges clients recurring fees for access and features. How it differs from competitors: It emphasizes surgical orchestration and tangible outcomes, backed by data such as a 22% reduction in scheduling costs and a 30% increase in surgical volume, and operates as a remote-first team across the United States. What the company aims to achieve: To make surgical scheduling more efficient, increase throughput, and grow revenue for healthcare providers.
Work here?Claim your company
Simplify's take
What believers are saying
- ImplantBase acquisition expanded Surgimate into medical device sales and inventory workflows by October 2026.
- A unified surgical-management platform can raise switching costs across hospitals, ASCs, and device distributors.
- GetApp and comparison lists keep Surgimate visible as a top 2026 surgery workflow vendor.
What critics are saying
- CaseCTRL, LiveData, HST Pathways, and Qventus crowd Surgimate’s buyer pipeline in 2026.
- Integrating ImplantBase and Surgimate risks product distraction, customer confusion, and delayed cross-sell revenue.
- If Banneker Partners sells or underinvests, Surgimate loses capital support and strategic patience.
What makes Surgimate unique
- Surgimate spans scheduling, patient coordination, and ImplantBase inventory logistics after February 2025.
- Kraig Brown became CEO in January 2025, replacing founder Rebecca Brygel.
- ModMed Momentum 2026 presence shows a specialized perioperative workflow brand with live market visibility.
Help us improve and share your feedback! Did you find this helpful?